The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

With an accuracy of 86%, the biomarker panel has the potential to be clinically useful in diagnosis, management, and ...

Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...

Sanofi has reported that the Phase III trial of rilzabrutinib for persistent or chronic ITP in the adult population, met its primary endpoint.

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a ...

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which ...

Acelyrin (SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...

Although patients with cancer value speedy access to new drugs, they are often willing to wait for strong evidence ...